Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-R09b in Parkinson's Disease
NCT06480461Phase 2Active, not recruiting
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of VGN-R09b in Parkinson's disease (PD), sponsored by Shanghai Vitalgen BioPharma Co., Ltd.. Started Sep 2024; status: active, not recruiting.
02
Drugs
VGN-R09b
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06480461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480461.